Trial Profile
Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 24 Oct 2023 Results assessing the maximum tolerated dose (MTD) of the PARP inhibitor olaparib in combination with radiotherapy in patients with head and neck squamous cell carcinoma presented at the 48th European Society for Medical Oncology Congress
- 27 Sep 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2024.
- 03 Aug 2021 Planned End Date changed from 1 Apr 2021 to 1 Jan 2022.